Mimedx (MDXG) Liabilities and Shareholders Equity (2010 - 2026)

Mimedx has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $281.0 million in Q2 2026.

• Quarterly Liabilities and Shareholders Equity fell 3.47% year-over-year to $281.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.3 billion (up 17.02% YoY) and the FY2025 annual result came in at $342.7 million, up 29.83% from the prior year.
• Liabilities and Shareholders Equity fell to $281.0 million in Q2 2026 per MDXG's latest filing, from $308.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $342.7 million in Q4 2025 and troughed at $168.2 million in Q1 2023.
• A 5-year average of $235.1 million and a median of $234.6 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity declined 9.87% in 2022, then soared 39.44% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $171.4 million in 2022, then soared by 39.44% to $239.0 million in 2023, then climbed by 10.4% to $263.9 million in 2024, then rose by 29.83% to $342.7 million in 2025, then fell by 17.99% to $281.0 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $281.0 million, $308.7 million, and $342.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.